...Have a histologically confirmed diagnosis of gastric adenocarcinoma and have been determined to be dMMR or MSI-H through immunohistochemistry or PCR, or PDL1 (22C3) CPS ≥ 10 through immunohistochemistry; 4. ...

...For different cohorts: Cohort A: Patients with locally advanced or metastatic NSCLC who have been confirmed by cytology or histology as inoperable or concurrent radiotherapy and chemotherapy, meet any of the following criteria: 1) Have not previously received systemic treatment for advanced or metastatic disease, except for patients with known EGFR sensitive mutations and ALK rearrangements; 2) After the failure of first-line platinum dual-drug chemotherapy; 3) Patients with known EGFR sensitive mutations or ALK rearrangements must have received at least one EGFR or ALK inhibitor treatment progression or intolerance; Cohort B: Patients with inoperable locally advanced, recurrent/metastatic gastric or gastroesophageal junction adenocarcinoma confirmed by cytology or histology, meeting any of the following criteria: 1) Locally advanced, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma (including signet ring cell carcinoma, mucinous adenocarcinoma, liver-like adenocarcinoma) that is newly diagnosed as unresectable, except for patients diagnosed as HER2-positive; 2) Unresectable or metastatic gastric/esophageal junction cancer with high microsatellite instability (MSI-H) or mismatch repair defect (dMMR) that has progressed after frontline treatment; 3) Locally advanced, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma that failed the second-line standard treatment, and PD-L1 CPS>1; Cohort C: Inoperable locally advanced recurrent or metastatic esophageal squamous cell carcinoma, meeting all the following criteria: 1) The previous first-line standard treatment failed; 2) Known endoscopes that tend to be completely obstructed and require interventional therapy to relieve the obstruction cannot be included; 3) After stent implantation in the esophagus or trachea, it cannot be included; 4) Patients who have a higher risk of bleeding or perforation due to the obvious invasion of the tumor into the adjacent organs of the esophageal lesion (aorta or trachea), or those who have formed a fistula, are not eligible; Cohort D: Inoperable patients with locally advanced, recurrent/metastatic hepatocellular carcinoma, the diagnosis of hepatocellular carcinoma is confirmed by histology/cytology or the patients with liver cirrhosis meet the clinical diagnosis of American Society for the Study of Liver Diseases (AASLD) hepatocellular carcinoma standard. ...

Among four patients with mismatch repair deficiency/microsatellite instability-high (dMMR/MSI-H) lesions, two achieved partial remission, and two displayed stable disease, resulting in a DCR of 100%....The application of sintilimab-based regimens achieved good disease control and tolerability for the real-world treatment of advanced G/GEJAC....Patients with dMMR/MSI-H lesions may also benefit from sintilimab-based regimens.